Second primary tumors in cancer patients: A retrospective analysis based on institutional tumor registry.

Authors

null

Luca Fumagalli

Division of Medical Oncology, European Institute of Oncology, Milan, Italy

Luca Fumagalli , Edoardo Botteri , Marzia Adelia Locatelli , Lucia Gelao , Carmen Criscitiello , Silvia Manunta , Nicole Rotmensz , Aron Goldhirsch , Giuseppe Curigliano

Organizations

Division of Medical Oncology, European Institute of Oncology, Milan, Italy, European Institute of Oncology, Milan, Italy, Division Medical Oncology, European Institute of Oncology, Milan, Italy

Research Funding

No funding sources reported

Background: The relative risk of developing a second tumor by site of primary tumor or gender is still unclear. Methods: We retrospectively analyzed data of 24,224 consecutive patients admitted to the European Institute of Oncology between 2000 and 2006 for a first primary invasive tumor. All the data were extracted from the institutional Tumor Registry. All tumors were registered and indexed within the same patient’s record. We limited the analysis to the patients who were diagnosed and received at least one treatment in IEO for their first primary tumor. Follow-up was based on the last registered patient’s control visit. Cumulative incidence was compared across different subgroups by means of the Gray test. The observed cases of second metachronous primary tumors was compared with the number of cancers we expected from the general Italian population. We used the standardized incidence ratio (SIR), defined as the ratio of the number of second cancers observed to the number of second cancers expected, to estimate the relative risk of second cancers, and we calculated 95% confidence intervals (95% CIs) by applying the Wilson and Hilferty approximation for chi-square percentiles. Results: In this population the 5-year cumulative incidence of a second tumor on the average population was 5.0%, SIR (CI 95%) was 1.3 (1.2-1.4). The Table reports details on observed versus expected second metachronous primary tumors by first tumor site. Conclusions: Cancer patients have a higher risk of a second primary tumor than general population.

First
primary
Head
and
neck
Digestive
organs and
peritoneum
Respiratory
and
intrathoracic
organs
Female
breast
Melanoma Skin Female
genital
organs
Male
genital
organs
Urinary
organs
Brain Thyroid
and other
endocrine
glands
Lymphatic
and
hemato-
poietic
tissues
Sarcoma Total
At risk 627 1,702 2,059 12,222 797 90 1,540 1,190 502 24 363 792 430 22,338
All patients Observed 46 61 149 524 45 9 54 64 53 2 8 51 19 1,085
Expected 25.1 73.5 97.4 391.4 26.2 4.8 39.8 77.2 25.5 0.3 8.3 27.2 11.8 808.5
SIR
(95% CI)
1.8
(1.3-2.5)
0.8
(0.6-1.1)
1.5
(1.3-1.8)
1.3
(1.2-1.5)
1.7
(1.3-2.3)
1.9
(0.9-3.6)
1.4
(1.0-1.8)
0.8
(0.6-1.1)
2.1
(1.6-2.7)
7.4
(0.8-25.7)
1.0
(0.4-1.9)
1.9
(1.4-2.5)
1.6
(1.0-2.5)
1.3
(1.2-1.4)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Cancer Prevention/Epidemiology

Track

Cancer Prevention/Epidemiology

Sub Track

Epidemiology

Citation

J Clin Oncol 31, 2013 (suppl; abstr 1595)

DOI

10.1200/jco.2013.31.15_suppl.1595

Abstract #

1595

Poster Bd #

8H

Abstract Disclosures

Similar Abstracts

First Author: Karthik Chamarti

First Author: Andrew Wellen

First Author: Eric Adjei Boakye

Abstract

2022 ASCO Genitourinary Cancers Symposium

Risk of secondary malignancies after pelvic radiation: A population-based analysis.

First Author: Andrew Salib